384 results on '"Wiedermann U"'
Search Results
2. Emerging targets for anticancer vaccination: PD-1
3. E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
4. 74MO HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer
5. 1676P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of HER-2/neu expressing lung metastases
6. 1421P Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)
7. Correction: E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
8. 22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases
9. Medical students’ knowledge and attitudes regarding vaccination against measles, influenza and HPV. An international multicenter study
10. Humoral and cellular immune responses and their kinetics vary in dependence of diagnosis and treatment in immunocompromised patients upon COVID-19 mRNA vaccination
11. Migration – epidemiologische, soziokulturelle und medizinische Aspekte: Überblick und Highlights des 2. Symposiums für Migrationsmedizin 2013
12. P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
13. 472P Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
14. 1536P HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
15. Allergen hybrids – next generation vaccines for Fagales pollen immunotherapy
16. Unterschiedliche Impfschemata in Europa: Führen alle Wege nach Rom?
17. Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
18. PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome
19. Spatial distribution of Her-2/neu and PD-L1 expression in lung metastases after active immunization with a Her-2/neu-targeting mimotope-based multipeptide B-cell vaccine in a mouse model
20. Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization
21. Neonatal monoassociation of mice with Bet v 1 producing recombinant Lactobacillus plantarum shifts immune response towards Th1 in a pollen allergy model: 21
22. Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides
23. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy
24. Vaccination of healthcare personnel in Europe: Update to current policies
25. Mucosal Immunity - Mucosal Tolerance
26. The European LABDEL project and its relevance to the prevention and treatment of allergies
27. New allergy intervention strategies: hitting the mucosal road
28. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities
29. Antibodies Generated by Vaccination with a HMW-MAA Mimotopes Suppress Human Melanoma Tumor Growth in SCID Mice
30. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1
31. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice
32. The anti-tumor capacity of a high molecular weight-melanoma-associated antigen mimotope vaccine depends on the exact mimicry of the antigenʼs epitope: 712
33. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
34. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy
35. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu: P991
36. Vaccination with a mimotope of the high molecular weight melanoma associated antigen induces anitbodies inhibiting melanoma tumor cell growth: P949
37. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice
38. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help
39. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice
40. Correction: E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
41. E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization
42. Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
43. Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours
44. Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
45. Breast Milk: Role in Neonatal Host Defense
46. Contributors
47. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen
48. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen
49. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1
50. Vitamin A Deficiency Increases Inflammatory Responses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.